Oxyphenisatine

CHEMBL245807 Phase 4 承認済み Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
317.3 g/mol
LogP
3.2
Phase
4

A stimulant laxative closely related to oxyphenisatin acetate, sharing the same mechanism and the same withdrawal history due to hepatotoxicity. It was used for constipation but discontinued due to liver injury risks.

分子量

317.3000 g/mol

LogP

3.20

TPSA

69.60 Ų

リピンスキーの五則

適合

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D構造

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

O=C1Nc2ccccc2C1(c1ccc(O)cc1)c1ccc(O)cc1

InChI

InChI=1S/C20H15NO3/c22-15-9-5-13(6-10-15)20(14-7-11-16(23)12-8-14)17-3-1-2-4-18(17)21-19(20)24/h1-12,22-23H,(H,21,24)

Molecular Formula

C20H15NO3

HBD / HBA

3 / 3

回転可能結合数

2

重原子数

24

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

A stimulant laxative closely related to oxyphenisatin acetate, sharing the same mechanism and the same withdrawal history due to hepatotoxicity. It was used for constipation but discontinued due to liver injury risks.

Yes, Oxyphenisatine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL245807. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 31315. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.